Physician profile
Shaye E Harrel
NPI 1487025086
$781.89
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $62.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.78 | 2021-2022 | |
| Gilead Sciences, INC. | $149.37 | 2021 | |
| Janssen Biotech, INC. | $87.18 | 2021 | |
| Abbvie INC. | $79.39 | 2021 | |
| Redhill Biopharma INC. | $55.80 | 2021 | |
| Merck Sharp & Dohme LLC | $32.37 | 2021 | |
| Intercept Pharmaceuticals, INC. | $29.32 | 2021 | |
| Pfizer INC. | $25.88 | 2021 | |
| Celgene Corporation | $25.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.96 | 2021 | |
| Qol Medical, LLC | $19.38 | 2021 | |
| Braintree Laboratories, INC. | $16.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaye Harrel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.